Time matters! – Why PK/PD is important for oligo development

June 5th, 2020|Categories: Past Webinars|

Presenter: Carl Amilon (AstraZeneca) Date: June 10, 2020 Description: This webinar will give an overview of how incorporating quantitative PK/PD aspects of an oligonucleotide will help you designing more informative experiments and help in translating to a human. We have all struggled with questions around the ...

Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial

May 15th, 2020|Categories: Alternative splicing, Clinical Development, Delivery, Immune Stimulation, Medicinal Chemistry, Pre-Clinical Research, Ribozyme, Toxicology|

Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP; CINRG DNHS Investigators. JAMA Neurol. 2020 May 26 Pubmed

Go to Top